
Genmab has struggled so far in 2021, but certain signs indicate the share may be regaining its momentum, according to an analysis from the Danish bank Jyske Bank.
Strong sales figures, fast-track acceptance of the drug tisotumab and the prospects of many new developments in the second half-year may generate tailwind for the company.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app